Trials / Recruiting
RecruitingNCT05953519
Meeting an Unmet Need in Multiple Sclerosis
Meeting an Unmet Need in Multiple Sclerosis (MS): An Evaluation of the Effectiveness of a Transdiagnostic Psychological Treatment and Its Outcomes
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Kessler Foundation · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objectives of this study is to examine the efficacy of the Unified Protocol in decreasing depression and anxiety among individuals with MS and the secondary outcomes (e.g., improved well-being, QOL, coping, etc.) that may occur in tandem.
Detailed description
The primary objectives of this study is to examine the efficacy of the Unified Protocol in decreasing depression and anxiety among individuals with MS and the secondary outcomes (e.g., improved well-being, QOL, coping, etc.) that may occur in tandem. To achieve this, the investigation has the following specific aims: Specific Aim 1: Conduct a pilot Randomized Controlled Trial (RCT) of the Unified Protocol among individuals with MS to determine the effectiveness of the intervention in reducing depression and anxiety. Hypothesis 1: Individuals who participate in the Unified Protocol intervention will report a decrease in their depression and anxiety compared to individuals in the control group. Specific Aim 2: Conduct a pilot RCT of the Unified Protocol among individuals with MS to determine the effectiveness of the intervention in improving secondary outcomes of psychological well-being, QOL, coping, and MS symptomatology over time. Hypothesis 2: Individuals who participate in the Unified Protocol intervention will report an increase in psychological well-being, QOL, coping, and MS symptomatology over time compared to participants in the control group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Unified Protocol | The Unified Protocol is a transdiagnostic intervention developed to treat depression and anxiety. |
Timeline
- Start date
- 2023-04-10
- Primary completion
- 2025-04-30
- Completion
- 2026-04-30
- First posted
- 2023-07-20
- Last updated
- 2023-07-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05953519. Inclusion in this directory is not an endorsement.